The DOI matches its Crossref record.
Propranolol for infantile hemangiomas: Early experience at a tertiary vascular anomalies center
Abstract
Objectives/Hypothesis: Propranolol has recently been introduced as a novel pharmacologic treatment for infantile hemangiomas. Systematic examination of this treatment in a tertiary care setting has not been described. This study explores the impact of propranolol on both proliferative and involuting hemangiomas at a tertiary vascular anomalies center. Study Design: Retrospective single institution review. Materials and Methods: We reviewed children treated with propranolol for problematic hemangiomas followed by a blinded prospective analysis of serial photographs taken during the course of their therapy. Parental questionnaires were obtained to evaluate perceived therapeutic response and complications to oral propranolol. Results: Thirty‐two children with complete photo documentation were treated with oral propranolol for infantile hemangiomas between September 2008 and June 2009. Twenty‐seven patients began therapy during the proliferative phase of their lesions (mean age, 4.9 months), whereas five patients began during the involutional phase (mean age, 19.4 months). Ninety‐seven percent of patients displayed improvement in the quality of their hemangiomas during propranolol therapy. Patients were determined to be excellent responders (n = 16, 50%), partial responders (n = 15, 47%), or nonresponders (n = 1, 3%). Partial and nonresponders received adjuvant therapy (75%, laser therapy; 31%, steroid injections). Ten patients experienced minor but reportable side effects to propranolol, including somnolence (27.2%), gastroesophageal reflux (9.1%), respiratory syncytial virus exacerbation (4.5%), and rash (4.5%). Conclusions: Propranolol may revolutionize the treatment of problematic hemangiomas that cause imminent functional or cosmetic sequelae. At therapeutic doses, propranolol is safe and effective in the majority of patients. Adjunctive therapies may still be required. Minor side effects, expected from beta‐blocker therapy, are common but easily managed. Laryngoscope, 2010
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Initiation and Use of Propranolol for Infantile Hemangioma: Report of a Consensus Conference
Drolet, B. A., Frommelt, P. C., Chamlin, S. L., Haggstrom, A., Bauman, N. M., Chiu, Y. E., Chun, R. H., Garzon, M. C., Holland, K. E., Liberman, L., et al. (2013) · Pediatrics · doi:10.1542/peds.2012-1691 · Cited by 591
Storch, C. H., & Hoeger, P. H. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.09848.x · Cited by 526
Diagnosis and Management of Infantile Hemangioma
Darrow, D. H., Greene, A. K., Mancini, A. J., Nopper, A. J., the SECTION ON DERMATOLOGY, S. O. O. A. N. S., Antaya, R. J., Cohen, B., Drolet, B. A., Fay, A., Fishman, S. J., et al. (2015) · Pediatrics · doi:10.1542/peds.2015-2485 · Cited by 293
A Randomized Controlled Trial of Propranolol for Infantile Hemangiomas
Hogeling, M., Adams, S., & Wargon, O. (2011) · Pediatrics · doi:10.1542/peds.2010-0029 · Cited by 283
Metadata
- Authors
- Buckmiller, L. M., Munson, P. D., Dyamenahalli, U., Dai, Y., & Richter, G. T.
- Venue
- The Laryngoscope
- Publisher
- Wiley
- Published
- 2010-03-22
- Volume
- 120
- Issue
- 4
- Pages
- 676-681
- ISSN
- 0023-852X (ISSN-L)
- 1531-4995
- OpenAlex
- W1991951767
- Cited by
- 203
- References
- 0
- FWCI
- 29.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.